Internal Reference Number: FOI_8510
Date Request Received: 10/03/2025 00:00:00
Date Request Replied To: 20/03/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq) - < 5 patients • Durvalumab (Imfinzi) - 0 • Nivolumab (Opdivo) - 0 • Pembrolizumab (Keytruda) - <5 patients • Chemotherapy - 8 patients • Radiotherapy - not given at this Trust • Chemotherapy AND Radiotherapy - not given at this Trust • Osimertinib - <5 patients | |
| Question Number 2: How many patients were treated in the past 3 months for gastric cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only • Zolbetuximab (Vyloy) | |
| Answer To Question 2: CAPOX (Capecitabine with Oxaliplatin) - 0 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0 • Lonsurf (Trifluridine - tipiracil) - 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - <5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy - <5 patients • Palliative care only • Zolbetuximab (Vyloy) - 0 | |
| Question Number 3: How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: CAPOX (Capecitabine with Oxaliplatin) - < 5 patients • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0 • Lonsurf (Trifluridine - tipiracil) - 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - , 5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - < 5 patients • Zolbetuximab (Vyloy) - 0 • Any other systemic anti-cancer therapy - 7 patients • Palliative care only | |
| Question Number 4: How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? | |
| Answer To Question 4: How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? - 15 patients | |
| Question Number 5: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? | |
| Answer To Question 5: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? - Not treated at this Trust. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
